Stock Events

Fortress Biotech 

$2.13
279
+$0.11+5.45% Today

Statistics

Day High
-
Day Low
-
52W High
10.35
52W Low
1.24
Volume
207,051
Avg. Volume
186,912
Mkt Cap
43.48M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

15MayConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-3.21
-2.16
-1.12
-0.07
Expected EPS
-1.73
Actual EPS
-1.03

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FBIO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adverum Biotechnologies
ADVM
Mkt Cap164.19M
Adverum Biotechnologies develops gene therapy products for patients suffering from rare and ocular diseases, competing in the same biotech innovation space as FBIO.
Agenus
AGEN
Mkt Cap327.59M
Agenus Inc. focuses on immuno-oncology, a field that overlaps with some of Fortress Biotech's projects in cancer treatment, making them direct competitors.
Alnylam Pharmaceuticals
ALNY
Mkt Cap32.95B
Alnylam Pharmaceuticals is pioneering in RNAi therapeutics, a novel form of treatment that could compete with FBIO's diverse biotech portfolio.
AMGEN
AMGN
Mkt Cap177.47B
Amgen is a larger biotechnology firm with a broad focus, including treatments for illnesses that FBIO also targets, making them a competitor by virtue of overlapping therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap16.14B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, directly competing with FBIO's interest in rare diseases.
Bluebird bio
BLUE
Mkt Cap133.39M
bluebird bio specializes in gene therapies for severe genetic diseases and cancer, areas that FBIO is also exploring, positioning them as competitors.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is at the forefront of gene editing, a revolutionary approach that could compete with FBIO's gene therapy projects.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences has a broad portfolio including oncology, infectious diseases, and inflammatory disorders, overlapping with FBIO's areas of interest.
Incyte
INCY
Mkt Cap14.29B
Incyte Corporation focuses on oncology and inflammation, directly competing with FBIO in the development of treatments for cancer and rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.12B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis, a rare disease area that FBIO is also interested in, making them competitors.

Analyst Ratings

7.5$Average Price Target
The highest estimate is $10.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Show more...
CEO
Lindsay Rosenwald
Employees
186
Country
US
ISIN
US34960Q1094
WKN
000A14SJV

Listings